The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01636505|
Recruitment Status : Unknown
Verified July 2012 by European Hospital.
Recruitment status was: Not yet recruiting
First Posted : July 10, 2012
Last Update Posted : July 10, 2012
The aim of this study is to performed a randomized controlled trial to evaluate the rate of genetic and chromosomal abnormalities in embryos obtained from GnRH-agonist long and GnRH-antagonist ovarian stimulation protocols.
Patients will be prospectively randomized in two groups: the first undergoing controlled ovarian stimulation in GnRH-agonist long protocol and the second following GnRH-antagonist ovarian stimulation regimen.
The end-points of the study include the number of genetically and chromosomally abnormal embryos, the pregnancy, the implantation and the healthy baby birth rate.
The patients included in PGS program were selected on the base of advanced maternal age, repeated pregnancy lost and implantation failure whereas the patients who were know to carry sex-linked or monogenic disorders were considered for PGD strategy.
The uterine abnormalities, endometriosis and endocrinal diseases were considered to be the exclusion factors.
|Condition or disease||Intervention/treatment||Phase|
|Embryo's Genetic and Chromosomal Quality||Drug: ghrh antagonist (cetrotide/orgalutran) Drug: gnrh agonist (suprefact)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||September 2012|
|Estimated Primary Completion Date :||February 2013|
|Estimated Study Completion Date :||September 2013|
Active Comparator: short protocol
gnrh agonist versus gnrh antagonist
Drug: ghrh antagonist (cetrotide/orgalutran)
cetrotide/orgalutran 0.25 mg
|Active Comparator: long protocol||
Drug: gnrh agonist (suprefact)
suprefact 5.5 ml
- The results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of embryos obtained from GnRH-agonist long and GnRH-antagonist ovarian stimulation protocol [ Time Frame: one year ]difference in embryos' genetic and chromosomal quality using two different ovarian stimulation protocol
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01636505
|European Hospital||Not yet recruiting|
|Rome, Italy, 00148|
|Contact: Ermanno Greco, MD 06-65975643 firstname.lastname@example.org|
|Principal Investigator: Ermanno greco, MD|